๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 12 Shanghai 9 Wuhan 7 Shenzhen 5 Guangzhou 5
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing12 Shanghai9 Wuhan7 Shenzhen5 Guangzhou5
All 32 locations
Target enrolment
to

Trials with a site in Beijing

12 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus
NCT07447986Systemic Lupus Erythematosus (SLE)
DrugSG301
Hangzhou Sumgen Biotech Co., Ltd.
Phase 2
120
Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Shenzhen, Guilin, Nanning
2026-03-26
Not yet open
The Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HC022 Injection in Subjects With SLE/CLE
NCT07306585Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
DrugHC022
HC Biopharma Inc.
Phase 1
32
Beijing
2025-12-30
Recruiting
A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus
NCT07444307Systemic Lupus Erythematosus (SLE)
Hangzhou Qihan Biotech Co., Ltd.
Phase 1
18
Hefei, Wuhan, Beijing
2025-12-15
Recruiting
The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE
NCT07185269Systemic Lupus Erythematosus (SLE)
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 1/2
198
Beijing
2025-09-24
Recruiting
Clinical Study of Cizutamig in Systemic Lupus Erythematosus
NCT07215663Systemic Lupus Erythematosus (SLE)
Candid Therapeutics
Phase 1
47
Beijing, Guangzhou, Luoyang, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai
2025-09-04
Recruiting
Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus
NCT07010835Systemic Lupus Erythematosus (SLE)
DrugYK012
Excyte Biopharma Ltd
Phase 1/2
189
Beijing
2025-08-25
Recruiting
A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
NCT06980597Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM), Systemic Sclerosis (SSc), ANCA Associated Vasculitis (AAV)
Beijing GoBroad Hospital
Phase 1
44
Beijing
2025-06
Recruiting
A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
NCT06978647Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), Inflammatory Myopathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
China Immunotech (Beijing) Biotechnology Co., Ltd.
Phase 1
12
Beijing
2025-05-19
Recruiting
CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)
NCT06822881Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc)
Beijing GoBroad Hospital
Phase 1
27
Beijing
2025-02-20
Recruiting
Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus
NCT06585514Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
Beijing GoBroad Hospital
Phase 1/2
18
Beijing
2024-10-17
Active, closed
An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).
NCT06335979Systemic Lupus Erythematosus, SLE
DrugPIT565
Novartis Pharmaceuticals
Phase 1
54
Beijing
2024-10-08
By invitation
An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
NCT05352919Systemic Lupus Erythematosus (SLE)
Biogen
Phase 3
864
Beijing, Dongguan, Guangzhou, Shenzhen, Zhongshan, Haikou, Shijiazhuang, Changsha
2022-06-10
Rows per page Showing 1–12 of 12
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 12 of those studies with a site in Beijing that also match the filters currently applied.

How many clinical trials are recruiting in Beijing?

9 of the 12 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 1 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Beijing), 12 studies
PhaseStudiesRecruitingShare
Phase 17558.3%
Phase 1/23325%
Phase 2118.3%
Phase 3108.3%

Most active sponsors

Lead sponsors with the most studies (Beijing)
Lead sponsorStudiesRecruiting
Beijing GoBroad Hospital33
Biogen10
Candid Therapeutics11
China Immunotech (Beijing) Biotechnology Co., Ltd.11
Excyte Biopharma Ltd11
Hangzhou Qihan Biotech Co., Ltd.11
Hangzhou Sumgen Biotech Co., Ltd.11
HC Biopharma Inc.10
Novartis Pharmaceuticals10
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.